February

Metabolomics, Proteomics, and Epigenetics

Why Oncologists Must Tailor Clinical Features to Their Needs

Promise and Pitfalls Along the Path to Personalized Care

The Duke Cancer Institute

To help oncology providers better understand drug mechanisms of action, and the economic implications of their use.

Review of the most recent evidence-based literature discussing breast, colorectal, lung, and ovarian cancers, in addition to melanoma and multiple myeloma.

How Much Do We Spend and How Can We Spend It Better?

Insights Into Value-Based Insurance Design in Oncology

Radical Changes in Payment Incentives and Elimination of Low-Value Care

Health Plans Continue to Seek Methods to Curtail Cancer Costs

Grim Reality Is a Bitter Pill to Swallow: Interview with Michael P. Link, MD, ASCO President

The Challenges Facing Oncologists Are Formidable

A New Era in Targeted Treatment Has Begun